Biogen (BIIB) Non-Current Deferred Tax Liability (2009 - 2026)

Biogen's Non-Current Deferred Tax Liability history runs 18 years deep, the most recent figure standing at $483.5 million for Q1 2026.

• In Q1 2026, Non-Current Deferred Tax Liability rose 262.99% year-over-year to $483.5 million; the TTM figure through Mar 2026 stood at $483.5 million (up 262.99% YoY), while the FY2025 annual figure was $507.6 million, up 166.46% from the prior year.
• Non-Current Deferred Tax Liability was $483.5 million for Q1 2026 at Biogen, down from $507.6 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $882.4 million in Q3 2024 to a low of $118.3 million in Q2 2025.
• Historically, Non-Current Deferred Tax Liability has averaged $435.5 million across 5 years, with a median of $480.6 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Non-Current Deferred Tax Liability jumped 310.42% in 2024, then plunged 79.97% in 2025.
• A 5-year view of Non-Current Deferred Tax Liability shows it stood at $334.7 million in 2022, then soared by 91.75% to $641.8 million in 2023, then sank by 70.32% to $190.5 million in 2024, then surged by 166.46% to $507.6 million in 2025, then decreased by 4.75% to $483.5 million in 2026.
• The last three Non-Current Deferred Tax Liability figures came in at $483.5 million (Q1 2026), $507.6 million (Q4 2025), and $358.1 million (Q3 2025), per Business Quant data.